Introduction
Dysregulated growth factor receptor signaling is a hallmark of human epithelial malignancies and occurs by a variety of means that may include autocrine or paracrine stimulation of growth factor receptors by de novo synthesis of growth factors, growth factor receptor overexpression, and mutation of growth factor receptors to cause their constitutive activation (Hanahan and Weinberg, 2000) . It has become evident within the last two decades that the large complement of proteolytic enzymes encoded by the vertebrate genome contributes to carcinogenesis not only by facilitating the degradation of extracellular matrix during invasion and metastasis, but rather has a pivotal role in all molecular processes associated with malignant transformation, including growth factor receptor dysregulation (LopezOtin and Hunter, 2010) . Matriptase (MT-SP1, epithin, TADG15) is a multi-domain, membrane-bound, trypsinlike serine protease belonging to the type II transmembrane serine protease family (Szabo and Bugge, 2008) . Matriptase has gathered considerable attention in the context of human carcinogenesis, because it is expressed with unusually high frequency in the epithelial compartment of human carcinomas of diverse origin, and because the level of expression or activity of matriptase is negatively correlated with clinical outcome (Uhland, 2006; List et al., 2006a) . In human tumors arising from simple, single-layered epithelia, matriptase is dysregulated by a variety of means that include overexpression, loss of inhibition by cognate transmembrane serine protease inhibitors, and increased zymogen auto-activation (Uhland, 2006; Szabo and Bugge, 2008) . Interest in matriptase as a potential promoter of epithelial carcinogenesis was also spurred by the observation that low-level expression of matriptase in the basal keratinocyte compartment of transgenic mice sufficed to both induce spontaneous ras-independent multistage squamous cell carcinogenesis, and dramatically potentiate ras-dependent malignant transformation in a proteolysisdependent manner (List et al., 2005) . Furthermore, while in normal mouse epithelium, matriptase expression is confined to a suprabasal post-mitotic compartment, where the protease is essential for initiating a terminal differentiation program, matriptase spatially translocates to the proliferative keratin-5 positive basal compartment during pre-malignant progression, and becomes abundant in the tumor cells of murine squamous cell carcinoma (List et al., 2006b) .
In this study, we document that matriptase is uniformly co-expressed in head and neck squamous cell carcinoma (HNSCC) with the receptor tyrosine kinase c-Met, the cognate receptor for pro-hepatocyte growth factor/scatter factor (proHGF/SF) (Park et al., 1986; Birchmeier et al., 2003) . Furthermore, we show by genetic epistasis analysis that spatially dysregulated matriptase exerts its oncogenic effects through a c-MetAkt-mammalian target of Rapamycin (mTor) signaling axis, activation of which is initiated by matriptasemediated conversion of signaling-incompetent singlechain proHGF/SF to signaling-competent two-chain HGF/SF. In the light of the high frequency of dysregulation of matriptase activity and the frequent upregulation of c-Met signaling in human carcinomas, the proteaseinitiated signaling pathway identified in this study may be relevant to a large number of epithelial malignancies.
Results
Matriptase and the HGF/SF receptor, c-Met, are co-expressed in human HNSCC and murine squamous cell carcinoma As in mice, matriptase is expressed in post-mitotic suprabasal cells of normal human squamous epithelium, but not in the proliferative basal compartment from which squamous cell carcinomas originate (List et al., 2006a) . Nevertheless, we found that matriptase was robustly expressed in seven of a survey of eight established HNSCC cell lines by western blot analysis ( Figure 1a ). Prompted by this observation and by the known capacity of matriptase to transform squamous epithelium when expressed at low levels in K5-positive basal keratinocytes of transgenic mice (List et al., 2006b) , we examined the expression of the membrane serine protease and its cognate transmembrane serine protease inhibitor, hepatocyte growth factor activator inhibitor (HAI)-1 in human HNSCC. As previously established for mouse squamous cell carcinoma (List et al., 2006b) , in silico data mining using the Oncomine microarray database did not reveal a dramatic change in the overall abundance of matriptase or HAI-1 transcripts in HNSCC in a meta-analysis of eight published gene expression array studies (Figures1b and b  0 ) . Expression of the ST14 gene, which encodes matriptase, was modestly increased in four studies, unchanged in one, and modestly decreased in the remaining three studies (Figure 1b) . Similarly, the expression of SPINT1, which encodes HAI-1, was markedly decreased in only one study, and it was relatively unchanged in seven studies (Figure 1b 0 ). We next took advantage of the availability of a previously generated, high-density tissue array (Molinolo et al., 2007) , which encompasses squamous cell carcinomas of different anatomical location (buccal mucosa, tongue, lip, gingiva, floor of mouth, larynx/ pharynx and other) and of different presumed etiology (alcohol/tobacco use, betel nut chewing, human papilloma virus infection and other) (Figure 1f ) to determine the frequency of expression and spatial location of matriptase in HNSCC. Interestingly, matriptase was expressed in all 72 primary tumors, as determined by immunohistochemistry. Expression was found throughout the tumors, including tumor cells that were located at the invasive front (Figures 1g-j) and were proliferative as determined by staining for the proliferation-associated marker, Ki67 (Figures 1c and c 0 , d and d 0 ). Taken together, this analysis established that matriptase expression is a ubiquitous feature of human HNSCC, and, therefore, that malignant transformation of human head and neck squamous epithelium, like malignant transformation of mouse squamous epithelium, may include the acquisition of matriptase expression by basal compartment keratinocytes with the capacity to undergo malignant transformation.
Of the considerable number of candidate substrates for matriptase that have been identified thus far, prourokinase plasminogen activator, protease activated receptor-2, matrix metalloproteinase-3 and proHGF/ SF, the precursor of the ligand for the tyrosine kinase receptor, c-Met, have been linked to carcinogenesis (Lee et al., 2000; Takeuchi et al., 2000; Jin et al., 2006; Camerer et al., 2010) . Whereas the role of proteaseactivated receptor-2 in squamous cell carcinogenesis is unexplored, matrix metalloproteinase-3 is tumor suppressive in this type of cancer (McCawley et al., 2004) , and no pre-malignant or malignant progression results from high-level expression of uPA and its cellular receptor in the basal keratinocyte compartment (Zhou et al., 2000) . Dysregulation of c-Met, however, is a particularly consistent feature of human HNSCC, and numerous studies have suggested a critical involvement of the HGF/SF-c-Met system in malignant transformation of squamous epithelium (Birchmeier et al., 2003; Seiwert et al., 2009 ) (see Discussion). We therefore, assessed the overlap in expression of c-Met and matriptase, a putative activator of the cognate ligand for c-Met. In agreement with earlier reports, a meta-analysis of the eight array studies used for assessing ST14 and . To determine if the co-expression of matriptase and c-Met observed in human HNSCC was replicated in mouse squamous cell carcinoma, we next analyzed the expression of matriptase and c-Met during chemically induced multi-stage mouse skin carcinogenesis. In hyperplastic/dysplastic epidermis, but not in normal epidermis, matriptase was strongly expressed in basal keratinocytes (Figures 2a-c ), in agreement with previous mRNA localization studies using mice with a LacZ marker gene in the St14 locus (List et al., 2006b) . Also, consistent with previous mRNA localization data, matriptase was abundant in the epithelial compartment of malignant lesions (Figure 2d ). Importantly, keratinocyte and tumor cell populations with high matriptase expression displayed high proliferation rates as determined by Ki67 expression (compare Figures 2a-d with   2a 0 -d 0 ). Similar to human HNSCC, c-Met was abundant in the epithelial compartment of both pre-malignant (data not shown) and malignant lesions (Figure 2e 0 ), with particularly elevated expression in basal keratinocytes of dysplastic lesions and carcinoma cells located at the invasive front. Furthermore, immunofluorescence analysis showed that the two molecules co-localized on the cell surface of pre-neoplastic keratinocytes (data not shown) and tumor cells (Figure 2e -e 00 ).
Matriptase amplifies proHGF/SF signaling through c-Met in primary keratinocytes Single-chain proHGF/SF is abundantly expressed by the stromal compartment of HNSCC. Single-chain proHGF/ SF binds c-Met with high affinity, but it is not signaling competent unless converted to active two-chain HGF/SF by endoproteolytic cleavage (Naldini et al., 1992 ) (see also Discussion). The ubiquitous co-expression of matriptase and c-Met in the epithelial compartment of both human Primary keratinocytes from newborn wild type (panels 1, 3 and 5 from top) and littermate K5-matriptase þ /0 (panels 2, 4, and 6 from top) were treated with either 2.5 nM proHGF/SF (lanes 1-7) or active HGF/SF (lanes 8 and 9) for 0 (lane 1), 5 (lanes 8 and 9), 10 (lane 2), 20 (lane 3), 30 (lanes 4 and 7), 45 (lane 5) and 60 (lane 6) min in the absence (lanes 1-6 and 8) or presence (lanes 7 and 9) of the serine protease inhibitor, aprotinin. Phosphorylated c-Met (panels 1 and 2 from top), phosphorylated Gab1 (panels 3 and 4 from top), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (bottom two panels) were detected by western blotting. (d-j) Elevated matriptase expression amplifies the migratory response of primary keratinocytes to single-chain proHGF/SF, but not to active two-chain HGF/SF. Scrape wounds were generated in confluent monolayers of primary keratinocytes from newborn wild type (d-f 0 ) and littermate K5-matriptase þ /0 (K5) (g-i 0 ) mice, and the monolayers were treated with vehicle 0 , and j). Furthermore, elevation of matriptase levels did not increase keratinocyte migration in response to active two-chain HGF/SF (Figure 3j ). Taken together, this suggests that matriptase potentiates c-Met-dependent migration of primary keratinocytes by proteolytic conversion of single-chain proHGF/SF to active two-chain HGF/SF.
Ablation of c-Met from basal keratinocytes in mice negates the oncogenic potential of matriptase We have previously shown that expression of matriptase in basal keratinocytes of mice (K5-Mat transgenic mice) suffices to cause ras-independent squamous cell carcinoma at one year of age and dramatically potentiates ras-dependent squamous cell carcinogenesis induced by the carcinogen, 7,12-dimethylbenzanthracene (DMBA) (List et al., 2005) . The above data all converged to suggest that matriptase could promote squamous cell carcinogenesis in humans and mice by amplifying a c-Met-dependent signaling cascade through the proteolytic conversion of single-chain proHGF/SF to active two-chain HGF/SF. To directly challenge this hypothesis in an in vivo context, we took advantage of the availability of mice carrying a floxed Hgfr allele (Huh et al., 2004) . By interbreeding of keratin14-Cre transgenic mice carrying floxed and null Hgfr alleles with K5-Mat transgenic mice, we generated mice with the simultaneous mis-expression of matriptase and ablation of c-Met from the basal keratinocyte compartment (K5-matriptase ;K14-Cre þ /0 ;Hgfr fl/ þ ; hereafter control mice) (see Supplementary Figure 1 for details on the breeding strategy). In agreement with a previous report (Chmielowiec et al., 2007) , genetic ablation of c-Met from the basal keratinocyte compartment was not associated with a notable effect on the development or homeostasis of the epidermis in mice that were followed for up to 1 year of age (see below and data not shown), which made it possible to directly assess the contribution of matriptase-mediated c-Met signaling to carcinogen-induced squamous cell carcinogenesis.
Repeated topical DMBA treatment of the epidermis led to tumor formation in about 40% of a cohort of control mice that were followed for up to 48 weeks, with the first tumors appearing 28 weeks after the initiation of treatment (Figures 4a-g ). Consistent with our previous report, expression of matriptase in basal keratinocytes dramatically potentiated DMBA-induced tumorigenesis (Figures 4a-g ). Thus, all of the c-Metsufficient K5-Mat mice that could be followed for up to 48 weeks after initiation of DMBA treatment presented with tumors with a median latency of just 24 weeks. Furthermore, whereas none of nine (0%) tumor-bearing control mice examined presented with malignant lesions, squamous cell carcinomas were detected in 10 of 16 (63%) c-Met-sufficient K5-Mat mice (Po0.002, w 2 test). Interestingly, and consistent with a critical role of proHGF/SF activation in matriptase-dependent tumorigenesis, c-Met ablation from the basal keratinocyte compartment negated the ability of matriptase to potentiate squamous cell carcinogenesis. Thus, the rate of tumor formation, tumor abundance, and tumor size of DMBA-treated c-Met-deficient K5-Mat mice did not differ significantly from DMBA-treated littermate control mice (Figures 4g-i) , and neither did the incidence of carcinoma in tumor-bearing mice examined microscopically at euthanization (one of five tumor-bearing mice, 20%, P ¼ N.S., w 2 test). We have previously shown that the effects of elevated keratinocyte matriptase during DMBA-induced carcinogenesis emulates the effects of constitutive protein kinase C and phosphatidylinositol 3-kinase (PI3K) activation, and that matriptase does not accelerate tumor formation in DMBA-treated epidermis when DMBA treatment is followed by protein kinase C and PI3K activation by phorbol 12-myristate 13-acetate (PMA) (List et al., 2005) . Just as was the case for elevated matriptase expression, c-Met ablation from basal keratinocytes had no measurable effect on the rate of tumor formation, tumor abundance, tumor size and malignant conversion rates when DMBA treatment was followed by repeated topical applications of PMA (Figures 4j-l and data not shown) . Importantly, this shows that the loss of the HGF/SF-c-Met signaling pathway from basal keratinocytes was not associated with a general impairment of the tumorigenic capacity of DMBA-initiated squamous epithelium per se.
Matriptase-induced pre-malignant progression is alleviated by c-Met ablation from basal keratinocytes Expression of matriptase in the basal keratinocyte compartment of mice is associated with a stereotypic set of progressive pre-malignant changes that also characterize human multi-stage squamous cell carcinogenesis. These include epidermal hyperplasia that transitions to focal and then multifocal dysplasia, follicular metaplasia, dermal fibrosis and dermal inflammation (List et al., 2005) . In light of the inability of matriptase to promote tumorigenesis in the absence of keratinocyte c-Met, we next examined to what extent matriptase-mediated pre-malignant progression was linked to local keratinocyte c-Met signaling. This was alopecia (a consequence of the follicular metaplasia) was dependent on keratinocyte c-Met. Thus, only a modest fur loss was apparent in c-Met-ablated matriptase transgenic mice, whereas extensive alopecia was a uniform feature of their c-Met-sufficient matriptase transgenic littermates (Figures 5a-c  0 ) . Remarkably, even at 1 year of age, c-Met-deficient K5-Mat epidermis seemed histologically normal or presented with only modest hyperplasia of the interfollicular epidermis (Figure 5d) . Furthermore, proliferation rates of basal keratinocytes of c-Met-deficient K5-Mat epidermis, as determined by BrdU incorporation, were only modestly higher than control or cMet-deficient epidermis, whereas c-Met-sufficient K5-Mat epidermis presented with a sixfold increase in keratinocyte proliferation (Figures 5e  and g ). Furthermore, c-Met ablation blocked matriptaseinduced expression of the epidermal stress-associated marker, keratin-6 (Figure 5f ), and prevented matriptaseinduced dermal fibrosis (Figures 5h-k) .
Matriptase-induced tumorigenesis through c-Met requires mTor activation
We have previously observed that matriptase-induced multi-stage squamous cell carcinogenesis is associated with robust activation of the PI3K-Akt pathway (List et al., 2005) , which is frequently activated in human epithelial malignancies (Vivanco and Sawyers, 2002) . Recently, mTOR was identified as a key target for the PI3K-Akt pathway during human and murine squamous cell carcinogenesis . Indeed, analysis of c-Met-sufficient K5-Mat mice revealed a robust mTor activity in hyperplastic, dysplastic and malignant lesions, as evidenced by phosphorylation of S6 ribosomal protein (Figures 6a-d) . Interestingly, whereas mTor activity was seen only in suprabasal keratinocytes in normal epidermis and hyperplastic lesions (Figures 6a and b) , dysplastic lesions were associated with strong mTor activity in both suprabasal and basal keratinocytes (Figure 6c ) and in all tumor cells of malignant lesions (Figure 6d ). To directly determine if mTor activation was causally related to matriptase/ c-Met-induced carcinogenesis, we took advantage of the availability of the potent and specific pharmacological mTor inhibitor, rapamycin. The skin of K5-Mat and wild-type littermates was treated with DMBA. The mice were then treated every 48 h with vehicle or with 5 mg/kg rapamycin, and tumor formation was followed for 33 weeks. We have previously established that this treatment regiment provides sustained mTor inhibition in squamous epithelium (Squarize et al., 2008) . As expected, all K5-Mat mice that could be followed for at least 24 weeks developed tumors with a median latency of 18 weeks (Figures 6e, h and k) , whereas tumors were not observed in DMBA-treated wild-type mice (Figures 6g and k) . However, rapamycin treatment completely prevented matriptase-mediated tumorigenesis, as assessed by outwards (Figures 6f and k) or microscopic (Figures 6g and j) examination, or matriptasedependent dysplasia (compare Figures 6h and i with j) . Interestingly, however, unlike c-Met ablation, mTor inhibition did not block matriptase-induced hyperplasia and keratinocyte hyperproliferation (Figures 6g,  j and l) . Taken together, these data demonstrate that matriptase-induced tumorigenesis through c-Met activation is absolutely dependent on the activation of the PI3K-Akt-mTor pathway.
Discussion
Compelling evidence has accumulated over the last two decades for an essential role of the HGF/SF-c-Met system in the initiation and progression of human cancer. c-Met activation is elicited primarily through either autocrine or paracrine HGF/SF stimulation, or ligand independently in tumor cells with a high expression of the receptor (Birchmeier et al., 2003; Knudsen and Vande Woude, 2008) . In the case of HNSCC, paracrine stimulation of tumor cells by stromal cell-produced HGF/SF has emerged as the primary pathway for pathogenic c-Met activation, with activating mutations in HGFR being more infrequent (Birchmeier et al., 2003; Seiwert et al., 2009 ).
An important feature of the HGF/SF-c-Met signaling cascade is that both single-chain proHGF/SF and double-chain HGF/SF bind c-Met with high affinity. However, the proteolytic conversion of single-chain proHGF/SF to the signaling competent two-chain form of HGF/SF is a compulsory step in both autocrine and paracrine activation of tumor cell c-Met. This is invariantly achieved by endoproteolytic cleavage of an R494-V495 bond, which is located within a phylogenetically conserved activation motif that is typically recognized by the family of trypsin-like serine proteases (Naldini et al., 1992) . Elegant structural, biochemical and cell biological studies suggest that proHGF/SF most likely engages c-Met in a heterotetrameric complex, in which the conformation of the two proHGF/SF subunits does not allow a productive interaction between the individual c-Met monomers. This conformational constraint is alleviated by proteolytic conversion of single-chain proHGF/SF to two-chain HGF/SF, which induces a significant structural change in the protein (Gherardi et al., 2006; Kirchhofer et al., 2007) . The most likely scenario, thus, is that the proteolytic conversion of single-chain proHGF/SF to active two-chain HGF/SF in HNSCC occurs directly on the tumor cell surface, as is also supported by the general propensity for extracellular proteolytic processes to be membrane-confined events, and by the limited capacity of HGF/SF to diffuse in extracellular space, due to its high affinity for heparan-sulfate proteoglycans (Hartmann et al., 1998) . Matriptase, when expressed concomitantly with c-Met on the keratinocyte cell surface, therefore, would be ideally positioned for activation of receptor-bound proHGF/SF. In our model for matriptase-promoted HNSCC (Figure 7 ), c-Metexpressing basal keratinocytes in close apposition to proHGF/SF-secreting mesenchymal cells (fibroblasts, inflammatory cells, endothelial/lymph endothelial cells) enhance their capacity to proliferate, override intrinsic antiproliferative/apoptotic signals or activate a proinvasive program by switching on expression of cell surface matriptase, which increases c-Met activity. In this scenario, it is the spatial location of matriptase (basal keratinocytes with high tumorgenic potential and c-Met expression vs suprabasal keratinocytes with no replicative potential) more than the magnitude of expression of matriptase that determines the capacity of the membrane protease to promote malignant transformation.
Besides HNSCC, matriptase and c-Met also may be coordinately expressed in several other carcinomas, suggesting that the matriptase-HGF/SF-c-Met pathway elucidated here could be relevant to a number of other epithelial malignancies. In support of this notion, Dickson and co-workers have shown a tight correlation between the expression of proHGF/SF, matriptase and c-Met mRNAs in mammary carcinoma and demonstrated that the simultaneous elevation of all three molecules is linked to poor disease outcome (Kang et al., 2003) .
The essential role of the HGF/SF-c-Met system in development, tissue repair and carcinogenesis is well established, but the identity of proteolytic enzymes that execute the obligate conversion of single-chain proHGF/SF to signaling competent two-chain HGF/SF in each of these contexts is less clear. Activation site cleavage of proHGF/SF can be undertaken in vitro or in cell-based assays by a substantial number of trypsin-like serine proteases, including the membrane-associated proteases, hepsin (Herter et al., 2005) and matriptase (Lee et al., 2000) , as well as the secreted proteases, Factor XIa, Factor XIIa, HGF activator, plasma kallikrein, plasmin and urokinase plasminogen activator (Naldini et al., 1992; Shimomura et al., 1995; Peek et al., 2002; Shanmukhappa et al., 2009) . Of this assembly of candidate proHGF/SF activators, HGF activator, hepsin and matriptase have displayed particularly favorable activation kinetics in purified systems (Shimomura et al., 1995; Herter et al., 2005; Owen et al., 2010) . Importantly, the current study extends these previous findings by providing direct genetic evidence that matriptase can activate proHGF/SF in vivo, and shows that this activation is functionally relevant to promoting carcinogenesis through the activation of a c-Met-dependent signaling pathway.
Physiological processes in which a crucial role of the HGF/SF system has been documented by loss-offunction studies in animals include placental formation, skeletal muscle, liver and kidney development, and the repair of liver, kidney and cutaneous injuries Schmidt et al., 1995; Uehara et al., 1995; Huh et al., 2004; Chmielowiec et al., 2007; Ma et al., 2009; Dai et al., 2010) . The findings reported here elevate matriptase to a prime status as a candidate activator of proHGF/SF also in these and other developmental and postnatal contexts. It is notable, however, that the null mutations generated thus far in any of the candidate proHGF/SF activators, including matriptase, have failed to replicate the developmental phenotypes of Hgf or Hgfr null mice in whole or in part (Carmeliet et al., 1994; Bugge et al., 1995; Gailani et al., 1997; Wu et al., 1998; List et al., 2002; Itoh et al., 2004; Pauer et al., 2004) . This would tentatively suggest that a limited or extensive functional redundancy may exist within the repertoire of proteases that serve to activate proHGF/SF in normal developmental and regenerative processes.
c-Met can activate a variety of proliferative, antiapoptotic and motility-promoting signaling pathways through the recruitment and phosphorylation of the adapter protein, Gab1, thereby inducing the activation of a number of downstream effectors. These include the extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) and PI3K-Akt-mTor pathways that have been recognized as key targets for tumor-promoting growth factors and cytokines during epithelial carcinogenesis (Birchmeier et al., 2003) . The latter pathway has attracted particular attention in relation to human HNSCC, due to the high frequency of mTor activation in this tumor type and the dramatic antitumor activity of the mTor inhibitor, rapamycin (Molinolo et al., 2007 ). Indeed, we observed that dysregulated matriptase induced mTor activation in both pre-malignant and malignant lesions, as evidenced by S6 phosphorylation. Furthermore, mTor activation was an absolute requirement for matriptase/c-Metinduced squamous cell carcinogenesis, as rapamycintreated mice with dysregulated matriptase remained entirely tumor free. Taken together, these results identify c-Met-induced activation of the PI3K-AktmTor pathway as one critical downstream mechanism for tumor promotion by dysregulated matriptase. Importantly, our study also provides evidence that activation of mTor, which is frequent in human HNSCC (Molinolo et al., 2007) and critical to the progression of this cancer in a large variety of experimental animal models (Amornphimoltham et al., 2005; Squarize et al., 2008; Raimondi et al., 2009) , can be attributed, at least in part, to paracrine c-Met activation facilitated by matriptase or other proHGF/SF activating proteases. However, mTor blockade, unlike genetic c-Met ablation, did not affect matriptase-induced keratinocyte hyperproliferation. This demonstrates that matriptase activates at least one additional proliferation-inducing signaling pathway, which is located downstream from c-Met, but upstream from mTor ( Figure 7) . Furthermore, the residual small increase in proliferation and other manifestations of pre-malignant progression that were observed in mice with dysregulated matriptase even after c-Met-ablation, could indicate the existence of (7), and this study.
additional matriptase proteolytic targets, besides proHGF/SF, of relevance to tumorigenesis. These residual phenotypes, however, may also be attributed to incomplete cre-mediated excision of the floxed Hgfr allele (Chmielowiec et al., 2007) .
In summary, the study shows that matriptase, a membrane serine protease whose activity is dysregulated in a variety of human epithelial cancers, promotes squamous cell carcinogenesis through a c-Met-AktmTOR signaling axis that is initiated by proteolytic conversion of the signaling-inert single-chain proHGF/ SF to a signaling-competent two-chain HGF/SF. The study furthermore suggests that matriptase could serve as a proHGF/SF activator in a variety of other cancers, as well as in normal developmental and tissue regenerative processes, as the membrane protease is expressed in a wide variety of human epithelial cell populations, as well as subsets of inflammatory cells.
Materials and methods

Human tissues
Paraffin blocks of formalin-fixed tissues from human squamous cell carcinoma of the oral and cavity and other locations were retrieved from the archives of the Oral and Pharyngeal Cancer Branch Tissue Repository (National Institute of Dental and Craniofacial Research, Bethesda, MD, USA). Comparative analysis of the incidence of expression of matriptase and c-Met proteins in human HNSCC was performed on a high-density HNSCC tissue microarray (Molinolo et al., 2007) .
Bioinformatic analysis
The Oncomine microarray database (http://www.oncomine. org (Rhodes et al., 2004) ) was used to perform a meta-analysis of the expression of human ST14, SPINT1, and HGFR genes across eight available studies of the transcriptome in squamous cell carcinoma of skin and head and neck region, as compared with their normal control tissues (Supplementary Table 1 ).
Mice
All experiments were performed in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited vivarium following Institutional Guidelines and standard operating procedures. The study was approved by the NIDCR Institutional Animal Care and Use Committee. All studies were strictly littermate controlled. The generation of Keratin5-matriptase transgenic mice (K5-matriptase þ /0 ) has been described (List et al., 2005) . Mice carrying a null allele of the cMet gene (Hgfr ; c Hgfr fl/ þ mice). The genotypes of all mice were determined by PCR of ear or tail DNA (see Supplementary Table 2 for primer sequences). Phenotypic changes were evaluated bi-weekly for a period of 52 weeks by visual inspection of the macroscopic appearance of skin and fur of the animal. At the end of the study the animals were injected intraperitoneally with 100 mg per g of body weight of 5-bromo-2 0 -deoxyuridine (BrdU) and euthanized by CO 2 inhalation after 2 h. Skin tissues from the midlumbar dorsal area were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 5-mm thick sections.
Preparation of proHGF/SF Human fibroblasts producing mouse single-chain proHGF/SF were kindly provided by Dr Charlotte Kuperwasser (Tufts University, Boston, MA, USA). The cells were maintained in Dulbecco's modified Eagle's medium containing high glucose and supplemented with 10% fetal bovine serum, penicillin/ streptomycin, and 2 mM L-glutamine (all Gibco, Invitrogen Corporation, Carlsbad, CA, USA) and were cultured in a 5% CO 2 -buffered tissue culture incubator. To collect the pro-HGF/SF, the cells were washed twice with sterile phosphatebuffered saline, incubated for 8 h in serum-free Dulbecco's modified Eagle's medium, after which the medium was replaced by fresh serum-free Dulbecco's modified Eagle's medium. The conditioned medium was collected after 72 h, concentrated 5-7 fold using Centriprep Ultracel YM-10 columns (Millipore, Bedford, MA, USA), aliquoted, and stored at À80 1C. To determine the quality and concentration of each preparation, 20 ml of the concentrated conditioned medium was loaded on 4-12% reducing sodium dodecyl sulfate-PAGE and analyzed by western blotting using a goat-anti human HGF primary antibody (R&D Systems, Minneapolis, MN, USA) with commercially produced human recombinant active HGF (R&D Systems) as a loading control.
Keratinocyte culture and proHGF/SF activation assays Primary keratinocytes from K5-matriptase þ /0 mice and wildtype littermate controls were isolated from newborn skin as described previously (Lichti et al., 1993) . Freshly isolated keratinocytes from three animals of each genotype were seeded on uncoated plastic six-well cell culture dishes at B500 000 cells per well, and grown in keratinocyte serum-free medium (K-SFM) supplemented with defined growth supplement (Invitrogen) for 24-48 h at 37 1C. The medium was changed to growth factor-free K-SFM, the cells were treated with 10 mM EGFR inhibitor AG1478 (Sigma, St Louis, MO, USA) for 1 h and 100 ng per ml of human recombinant single-chain proHGF/SF (see below) or active two-chain HGFSF (R&D Systems) were added. To determine the time course and the level of activation of the HGF-dependent signaling pathway, the cell culture medium was aspirated, and the cells were lysed in buffer containing 2% sodium dodecyl sulfate, 1% glycerol, 62.5 mM Tris-HCl pH 6.8, with 1 Â protease inhibitor cocktail and 1 Â phosphatase inhibitor cocktails 1 and 2 (all from Sigma). The protein concentration was determined by BCA assay (Pierce, Rockford, IL, USA) and 40 mg of total protein (Pierce) was loaded on 4-12% reducing sodium dodecyl sulfate-PAGE and analyzed by western blotting using a polyclonal sheep anti-human Matriptase (R&D Systems), rabbit anti-human phospho cMet, phospho-Gab1, or rabbit anti human GAPDH primary antibodies (all Cell Signaling Technology, Beverly, MA, USA). To assess the effect of the HGF/SF on the motility of epithelial cells, freshly isolated primary keratinocytes from skins of three K5-matriptase þ /0 and three wild-type littermate newborn mice were seeded on uncoated plastic six-well cell culture dishes at 500 000 cells per well, and grown in K-SFM supplemented with defined growth supplement for 24 h at 37 1C. Then the medium was aspirated, and replaced with K-SFM without growth supplement with 100 ng per ml of human recombinant single-chain proHGF/SF or active two-chain HGF. Aprotinin was added to cells to a final concentration of 2 mM when indicated. A scratch in the cell monolayer was introduced with a 20P pipette tip (Molecular BioProducts, San Diego, CA, USA). The cell migration into the denuded area was quantified after 24 h. The relative migration rate is presented as a mean of two independent experiments.
Chemical carcinogenesis
One-stage carcinogenesis. The dorsal skin of 6-to 8-week-old mice was shaved and treated 2 days later with a topical application of 25 mg DMBA (Sigma) in 100 ml acetone or with 100 ml acetone alone. The treatment was repeated every 3 weeks for a period of 39 weeks.
Two-stage carcinogenesis. The dorsal skin of 6-to 8-week-old mice was shaved and treated after 2 days with a single topical application of 25 mg DMBA in 100 ml acetone (Sigma), followed after 2 weeks by biweekly applications of 12 mg PMA (Sigma) for 20 weeks. The first appearance, number and size of the tumors in both groups of carcinogen-treated mice were monitored every 3 weeks. Mice with ulcerating tumors or tumors reaching a diameter of more than 1 cm were euthanized by CO 2 inhalation before the termination of the study. After euthanasia, tumors and skin from the treated area were fixed overnight in 4% paraformaldehyde, and processed for histological analysis as described above.
Rapamycin treatment
The dorsal skin of K5-matriptase þ /0 and littermate wild-type mice in an FVB/NJ background was shaved and treated after 2 days with a topical application of 50 mg DMBA in 200 ml acetone at 6 and 18 weeks. Starting 1 week after the first application of DMBA, mice of both genotypes were randomly divided into two groups and treated every other day for 33 weeks by intraperitoneal injections of 5 mg per g of body weight of rapamycin (LC Laboratories, Woburn, MA, USA) in 50 ml phosphate-buffered saline with 5.2% PEG400 and 5.2% Tween80 (vehicle). Control animals were treated in parallel with 50 ml of vehicle alone. The appearance of the tumors in carcinogen-treated mice was monitored every week. Mice with ulcerating tumors or tumors reaching a diameter of more than 1 cm were euthanized by CO 2 inhalation before the termination of the study.
Immunohistochemistry and immunofluorescence
Five-mm-thick sections of mouse and human tissues were prepared as described above. Antigens were retrieved by 20 min of boiling in 0.01 M sodium citrate, pH6.0, and the endogenous peroxidase activity was quenched by incubating the tissues in 3% hydrogen peroxide for 20 min at room temperature. The sections were blocked for 1 h at room temperature with 2% bovine serum albumin in phosphatebuffered saline, incubated with primary sheep anti-matriptase, goat anti-cMet (both R&D Systems), rabbit anti-phospho Akt, rabbit anti-phospho S6 (both Cell Signaling Technology), rat anti-BrdU (Axyll, Westbury, NY, USA), or rabbit anti-Ki67 (Novocastra, Newcastle Upon Tyne, UK) antibodies overnight at 4 1C. For immunohistochemistry, the bound antibodies were visualized using an appropriate biotin-conjugated secondary antibody and a Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA), using 3,3 0 -diaminobenzidine as substrate (Sigma). For detection of matriptase and cMet by immunofluorescence, the primary antibodies were visualized with NL637 conjugated donkey anti-sheep (R&D Systems) and Cy3 conjugated rabbit anti-goat (Sigma) secondary antibodies, respectively. Sections were then mounted with Vectashield HardSet Mounting Medium (Vector Laboratories) and the images were acquired using LSM700 confocal microscope system and ZEN2009 software (both Carl Zeiss MicroImaging GmbH, Jena, Germany).
